|
|
|
| The immune profiles and “minimizing tacrolimus” strategy for long-term survival recipients after liver transplantation |
| Jun-Jun Jia a , b , Shi-Yu Zhang a , b , Jun Yu a , b , Hai-Yang Xie a , b , Lin Zhou a , b , Shu-Sen Zheng a , b , ∗ |
a Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
b NHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou 310003, China
∗ Corresponding author at: Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
E-mail address: shusenzheng@zju.edu.cn (S.-S. Zheng). |
|
|
|
|
Abstract Liver transplantation (LT) has become a major and effective therapeutic approach for end-stage liver disease [1]. However, 10-year graft and patient survival rates remained low with 54% and 61%, respectively [2]. Improving the outcome of long-term LT has become a major focus of the transplantation community.
|
|
|
|
|
|
|
|
|
2021, Vol. 20 
